ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Voriconazole

Also written as “voriconazole”, “voriconazole (Vfend)” and “oral voriconazole”.

Its studies are mostly in Aspergillosis · Mycoses · Invasive Fungal Infections · Candidemia · Candidiasis, led by 3 companies.

Drug pageVoriconazole: every studyAll 77 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Aug 31, 200523 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer200 open or runningphase 4since Aug 31, 2005Aug 25, 2005none ahead
Yung Shin Pharm. Ind.its history only20 open or runningphase 4since Sep 21, 2016Sep 21, 2016none ahead
Chong Kun Dang Pharmaceuticalits history only10 open or runningphase 1since Dec 13, 2015Dec 13, 2015none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 6 studies since Aug 25, 2005.

  1. Feb 6, 2006Phase 4 study in Invasive Fungal InfectionsNCT00288197 · 77 enrolled · China
  2. Feb 9, 2006Phase 3 study in Antifungal Prophylaxis of Invasive Fungal InfectionsNCT00289991 · 489 enrolled · Canada, Czech Republic, Egypt and more
  3. Mar 7, 2006Phase 4 study in MycosesNCT00300677 · 12 enrolled · United States
  4. Oct 19, 2007Phase 4 study in CandidemiaNCT00548262 · 54 enrolled · Brazil, Chile, Colombia and more
  5. Nov 9, 2007Phase 2 study in PharmacokineticsNCT00556998 · 26 enrolled · United States
  6. Feb 8, 2008Phase 4 study in AspergillosisNCT00620074 · 6 enrolled · United States
  7. Mar 27, 2008Phase 4 study in CandidiasisNCT00647907 · 7 enrolled · Taiwan
  8. May 29, 2008Phase 3 study in Candidiasis, InvasiveNCT00689338 · 216 enrolled · Austria, Belgium, Canada and more
  9. Aug 20, 2008Phase 2 study in CandidiasisNCT00739934 · 40 enrolled · United States
  10. Feb 3, 2009Phase 3 study in Invasive AspergillosisNCT00836875 · 31 enrolled · United States, Canada, Czechia and more
  11. Mar 2, 2009Phase 1 study in Healthy VolunteersNCT00855101 · 35 enrolled · Belgium
  12. Jul 13, 2009Phase 4 study in AspergillosisNCT00940017 · 24 enrolled · United States
  13. Mar 10, 2010Phase 3 study in CandidiasisNCT01092832 · 23 enrolled · China, Czech Republic, Hong Kong and more
  14. Jun 27, 2011Phase 2 study in AspergillosisNCT01383993 · 21 enrolled · Japan

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Cytochrome P450 51 inhibitor”ChEMBL 37, by rule

Studies

All 20 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01383993Aspergillosis · Japan2CompletedMay 201321
NCT01092832Candidiasis · China, Czech Republic, Hong Kong and more3TerminatedMay 201323
NCT00940017Aspergillosis · United States4CompletedOct 200824
NCT00855101Healthy Volunteers · Belgium1CompletedJul 200935
NCT00836875Invasive Aspergillosis · United States, Canada, Czechia and more3TerminatedMay 201331
NCT00739934Candidiasis · United States2CompletedOct 200940
NCT00689338Candidiasis, Invasive · Austria, Belgium, Canada and more3CompletedMay 2010216
NCT00647907Candidiasis · Taiwan4Completed7
NCT00620074Aspergillosis · United States4TerminatedFeb 20096
NCT00556998Pharmacokinetics · United States2CompletedDec 200926
NCT00548262Candidemia · Brazil, Chile, Colombia and more4CompletedOct 200954
NCT00300677Mycoses · United States4CompletedAug 200812
NCT00289991Antifungal Prophylaxis of Invasive Fungal Infections · Canada, Czech Republic, Egypt and more3CompletedFeb 2009489
NCT00288197Invasive Fungal Infections · China4CompletedJun 200777
NCT00174473Neutropenia2Completed49
NCT00159822Aspergillosis · France3CompletedDec 200848
NCT00150345Neutropenia · Germany3CompletedApr 2009147
NCT00150319Renal Insufficiency · United States2TerminatedOct 20051
NCT00143312Invasive Fungal Infections · Belgium, France, Germany and more4CompletedApr 200845
NCT00136968Mycoses1Completed12

How it is read

Names in the registry

  • “Voriconazole”, 13 entries
  • “voriconazole”, 7 entries
  • “voriconazole (Vfend)”, 3 entries
  • “oral voriconazole”, 1 entry
  • “Vaway”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.